BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 31344053)

  • 1. The application of nano-enrichment in CTC detection and the clinical significance of CTCs in non-small cell lung cancer (NSCLC) treatment.
    Wei T; Zhu D; Yang Y; Yuan G; Xie H; Shen R
    PLoS One; 2019; 14(7):e0219129. PubMed ID: 31344053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating Tumor Cells Predict Prognosis Following Tyrosine Kinase Inhibitor Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Patients.
    Yang B; Qin A; Zhang K; Ren H; Liu S; Liu X; Pan X; Yu G
    Oncol Res; 2017 Nov; 25(9):1601-1606. PubMed ID: 28474575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of circulating tumor cells in evaluation of prognosis and treatment response in advanced non-small-cell lung cancer.
    Zhou J; Dong F; Cui F; Xu R; Tang X
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):825-833. PubMed ID: 28289866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating tumor cells predict prognosis following secondline AZD 9291 treatment in EGFR-T790M mutant non-small cell lung cancer patients.
    Yang B; Zheng D; Zeng Υ; Qin A; Gao J; Yu G
    J BUON; 2018; 23(4):1077-1081. PubMed ID: 30358214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumor cells as a response monitor in stage IV non-small cell lung cancer.
    Shishido SN; Carlsson A; Nieva J; Bethel K; Hicks JB; Bazhenova L; Kuhn P
    J Transl Med; 2019 Aug; 17(1):294. PubMed ID: 31462312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic role of circulating tumor cells in patients with EGFR-mutated or ALK-rearranged non-small cell lung cancer.
    Tong B; Xu Y; Zhao J; Chen M; Zhong W; Xing J; Wang M
    Thorac Cancer; 2018 May; 9(5):640-645. PubMed ID: 29582563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluid biopsy for circulating tumor cell identification in patients with early-and late-stage non-small cell lung cancer: a glimpse into lung cancer biology.
    Wendel M; Bazhenova L; Boshuizen R; Kolatkar A; Honnatti M; Cho EH; Marrinucci D; Sandhu A; Perricone A; Thistlethwaite P; Bethel K; Nieva J; Heuvel Mv; Kuhn P
    Phys Biol; 2012 Feb; 9(1):016005. PubMed ID: 22307026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups.
    Lindsay CR; Faugeroux V; Michiels S; Pailler E; Facchinetti F; Ou D; Bluthgen MV; Pannet C; Ngo-Camus M; Bescher G; Caramella C; Billiot F; Remon J; Planchard D; Soria JC; Besse B; Farace F
    Ann Oncol; 2017 Jul; 28(7):1523-1531. PubMed ID: 28633480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between circulating tumour cell count and prognosis following chemotherapy in patients with advanced non-small-cell lung cancer.
    Zhang Z; Xiao Y; Zhao J; Chen M; Xu Y; Zhong W; Xing J; Wang M
    Respirology; 2016 Apr; 21(3):519-25. PubMed ID: 26661896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR-Mutated Advanced Non-Small-Cell Lung Cancer Patients Treated With First-Line EGFR Tyrosine Kinase Inhibitors.
    Jiang T; Zhao J; Zhao C; Li X; Shen J; Zhou J; Ren S; Su C; Zhou C; O'Brien M
    Clin Lung Cancer; 2019 Mar; 20(2):124-133.e2. PubMed ID: 30587399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer.
    Lindsay CR; Blackhall FH; Carmel A; Fernandez-Gutierrez F; Gazzaniga P; Groen HJM; Hiltermann TJN; Krebs MG; Loges S; López-López R; Muinelo-Romay L; Pantel K; Priest L; Riethdorf S; Rossi E; Terstappen L; Wikman H; Soria JC; Farace F; Renehan A; Dive C; Besse B; Michiels S
    Eur J Cancer; 2019 Aug; 117():60-68. PubMed ID: 31254940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.
    Yanagita M; Redig AJ; Paweletz CP; Dahlberg SE; O'Connell A; Feeney N; Taibi M; Boucher D; Oxnard GR; Johnson BE; Costa DB; Jackman DM; Jänne PA
    Clin Cancer Res; 2016 Dec; 22(24):6010-6020. PubMed ID: 27281561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.
    Punnoose EA; Atwal S; Liu W; Raja R; Fine BM; Hughes BG; Hicks RJ; Hampton GM; Amler LC; Pirzkall A; Lackner MR
    Clin Cancer Res; 2012 Apr; 18(8):2391-401. PubMed ID: 22492982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantification of rare circulating tumor cells in non-small cell lung cancer by ligand-targeted PCR.
    Lou J; Ben S; Yang G; Liang X; Wang X; Ni S; Han B
    PLoS One; 2013; 8(12):e80458. PubMed ID: 24324600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detecting circulating tumor cells in patients with advanced non-small cell lung cancer.
    Xu YH; Zhou J; Pan XF
    Genet Mol Res; 2015 Sep; 14(3):10352-8. PubMed ID: 26345975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a highly sensitive and specific method for detection of circulating tumor cells harboring somatic mutations in non-small-cell lung cancer patients.
    Breitenbuecher F; Hoffarth S; Worm K; Cortes-Incio D; Gauler TC; Köhler J; Herold T; Schmid KW; Freitag L; Kasper S; Schuler M
    PLoS One; 2014; 9(1):e85350. PubMed ID: 24465542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-therapeutic circulating tumor cell-associated white blood cell clusters predict poor survival in patients with advanced driver gene-negative non-small cell lung cancer.
    Wang Y; Liu Y; Zhang Z; Lu B; Gao Y; Tong L; Hu M; Lin PP; Li B; Zhang T
    BMC Cancer; 2023 Jun; 23(1):578. PubMed ID: 37349714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolation and molecular analysis of circulating tumor cells from lung cancer patients using a microfluidic chip type cell sorter.
    Watanabe M; Kenmotsu H; Ko R; Wakuda K; Ono A; Imai H; Taira T; Naito T; Murakami H; Abe M; Endo M; Nakajima T; Koh Y; Takahashi T
    Cancer Sci; 2018 Aug; 109(8):2539-2548. PubMed ID: 29900633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive and prognostic value of folate receptor-positive circulating tumor cells in small cell lung cancer patients treated with first-line chemotherapy.
    Shen J; Zhao J; Jiang T; Li X; Zhao C; Su C; Zhou C
    Oncotarget; 2017 Jul; 8(30):49044-49052. PubMed ID: 28467771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of circulating tumor cells' reduction in patients with extensive small-cell lung cancer.
    Normanno N; Rossi A; Morabito A; Signoriello S; Bevilacqua S; Di Maio M; Costanzo R; De Luca A; Montanino A; Gridelli C; Rocco G; Perrone F; Gallo C
    Lung Cancer; 2014 Aug; 85(2):314-9. PubMed ID: 24882383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.